Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 15/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12037721 | 0.96 | CLPP (0.51) | CLPPPOLBNPC1TP53RAB9A | |
| SCHEMBL745441 | 0.94 | POLB (0.46) | CLPPPOLBNPC1TP53RAB9A | |
| SCHEMBL763063 | 0.92 | CLPP (0.52) | CLPPPOLBNPC1TP53RAB9A | |
| SCHEMBL10225230 | 0.92 | CLPP (0.48) | CLPPPOLBNPC1TP53RAB9A | |
| SCHEMBL13184826 | 0.90 | POLB (0.47) | CLPPPOLBNPC1TP53RAB9A | |
| SCHEMBL747045 | 0.89 | CLPP (0.45) | CLPPPOLBNPC1TP53RAB9A | |
| SCHEMBL747072 | 0.88 | POLB (0.46) | POLBNPC1TP53RAB9AL3MBTL1 | |
| SCHEMBL748454 | 0.88 | POLB (0.46) | POLBNPC1TP53RAB9AL3MBTL1 | |
| SCHEMBL748483 | 0.88 | CYP3A4 (0.48) | POLBNPC1TP53RAB9ACYP3A4 | |
| SCHEMBL749491 | 0.86 | POLB (0.45) | POLBNPC1TP53RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |